Transthyretin Amyloidosis (ATTR)- Market Insights, Epidemiology and Market Forecast-2027
This report can be delivered to the clients within 24 hours
DelveInsight’s Transthyretin Amyloidosis (ATTR)- Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Transthyretin Amyloidosis (ATTR) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Transthyretin Amyloidosis (ATTR) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
Transthyretin Amyloidosis (ATTR) - Disease Understanding and Treatment Algorithm
Transthyretin (earlier known as prealbumin) is an abundant, soluble, ?-strand rich 55 kDa homotetramer serum protein that is responsible for the transportation of both vitamin A (via retinol-binding protein) and thyroxin throughout the body. TTR is also involved in the binding and redistribution of ?-amyloid in the choroid plexus as well as in the retention of T4 in the cerebral spinal fluid (CSF). TTR may sometimes dissociate into its 127 amino acid monomeric subunits and undergo aberrant changes to form amyloidogenic intermediates. These intermediates then might self-associate to become amyloid fibrils that accumulate as amyloid deposits throughout the body, resulting in Transthyretin Amyloidosis.
Transthyretin Amyloidosis can be sub-classified as wild-type (wt) or hereditary, and the latter is then further sub-divided into familial amyloid polyneuropathy (FAP) and familial amyloid cardiomyopathy (FAC).
The DelveInsight Transthyretin Amyloidosis (ATTR) market report gives the thorough understanding of the Transthyretin Amyloidosis (ATTR) by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Transthyretin Amyloidosis (ATTR) in the US, Europe, Japan and China.
Transthyretin Amyloidosis (ATTR) Epidemiology
The Transthyretin Amyloidosis (ATTR) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 8 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Diagnosed Prevalent Population of ATTR, Type-specific Diagnosed Prevalent Cases and Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy]scenario of Transthyretin Amyloidosis (ATTR) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2016-2027.
According to DelveInsight, total prevalent population of ATTR in the 7 major markets ranges from approximately 19,197 cases in 2016 to XXX cases in 2027, growing at a CAGR of XX% during the study period [2016-2027].
DelveInsight also estimates higher prevalence of ATTR in the Italy with 2,044 cases in 2016 followed by France. On the other hand, United Kingdom has the lowest prevalent population in 2016.
DelveInsight estimates that the diagnosed prevalent population of ATTR will significantly increase with CAGR of XX % during the study period [2016-2027]
Hereditary transthyretin amyloidosis (hATTR) cases are segmented in to two segments which includes Familial Amyloid Polyneuropathy (FAP) and Familial Amyloid Cardiomyopathy (FAC) cases. In 2016, there were 5,201 cases of Familial Amyloid Polyneuropathy and XXX cases of Familial Amyloid Cardiomyopathy in the 7MM
Transthyretin Amyloidosis (ATTR) Drug Chapters
This segment of the Transthyretin Amyloidosis (ATTR) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Current treatment options for patients with TTR amyloidosis are limited, with only symptomatic treatment and transplantation. For patients diagnosed with TTR-FAP who have a mild or moderate disease and confirmed by genetic testing and biopsy, a liver transplant is the current standard of care. However, symptomatic treatment is used to provide immediate relief.
Various mechanisms leading to TTR misfolding and fibril formation identified TTR tetramer stabilization as a rate-limiting event, leading to the development of several new pharmacologic therapies for patients with TTR-FAP. These stabilizing agents can be prescribed at an early stage in anticipation of liver transplantation, or, potentially, delaying the need for liver transplant. Drugs use in the treatment of ATTR include-Tafamidis (disease-modifying agent that kinetically stabilizes) and Diflunisal (This drug is an NSAID that stabilizes TTR tetramers in vitro, preventing disaggregation, monomer release and amyloid fibril formation by misfolded TTR monomers).
Transthyretin Amyloidosis (ATTR) Market Outlook
The Transthyretin Amyloidosis (ATTR) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
FDA has approved few drugs such as Vyndaqel (Pfizer Inc), Onpattro (Alnylam Pharmaceuticals), Tegsedi (Ionis Pharmaceuticals /Akcea Therapeutics) which are used for the treatment of Transthyretin Amyloidosis (ATTR).
Key players such as Corino Therapeutics are involved in developing therapies for Transthyretin Amyloidosis (ATTR). Expected launch of emerging therapies such as CRX-1008: Corino Therapeutics therapies will significantly impact the Transthyretin Amyloidosis (ATTR) market during the study period (2016-2027).
Transthyretin Amyloidosis (ATTR) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Transthyretin Amyloidosis (ATTR) Report Insights
DelveInsight’s Transthyretin Amyloidosis (ATTR)- Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Transthyretin Amyloidosis (ATTR) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Transthyretin Amyloidosis (ATTR) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan
Transthyretin Amyloidosis (ATTR) - Disease Understanding and Treatment Algorithm
Transthyretin (earlier known as prealbumin) is an abundant, soluble, ?-strand rich 55 kDa homotetramer serum protein that is responsible for the transportation of both vitamin A (via retinol-binding protein) and thyroxin throughout the body. TTR is also involved in the binding and redistribution of ?-amyloid in the choroid plexus as well as in the retention of T4 in the cerebral spinal fluid (CSF). TTR may sometimes dissociate into its 127 amino acid monomeric subunits and undergo aberrant changes to form amyloidogenic intermediates. These intermediates then might self-associate to become amyloid fibrils that accumulate as amyloid deposits throughout the body, resulting in Transthyretin Amyloidosis.
Transthyretin Amyloidosis can be sub-classified as wild-type (wt) or hereditary, and the latter is then further sub-divided into familial amyloid polyneuropathy (FAP) and familial amyloid cardiomyopathy (FAC).
The DelveInsight Transthyretin Amyloidosis (ATTR) market report gives the thorough understanding of the Transthyretin Amyloidosis (ATTR) by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Transthyretin Amyloidosis (ATTR) in the US, Europe, Japan and China.
Transthyretin Amyloidosis (ATTR) Epidemiology
The Transthyretin Amyloidosis (ATTR) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 8 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Diagnosed Prevalent Population of ATTR, Type-specific Diagnosed Prevalent Cases and Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy]scenario of Transthyretin Amyloidosis (ATTR) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2016-2027.
According to DelveInsight, total prevalent population of ATTR in the 7 major markets ranges from approximately 19,197 cases in 2016 to XXX cases in 2027, growing at a CAGR of XX% during the study period [2016-2027].
DelveInsight also estimates higher prevalence of ATTR in the Italy with 2,044 cases in 2016 followed by France. On the other hand, United Kingdom has the lowest prevalent population in 2016.
DelveInsight estimates that the diagnosed prevalent population of ATTR will significantly increase with CAGR of XX % during the study period [2016-2027]
Hereditary transthyretin amyloidosis (hATTR) cases are segmented in to two segments which includes Familial Amyloid Polyneuropathy (FAP) and Familial Amyloid Cardiomyopathy (FAC) cases. In 2016, there were 5,201 cases of Familial Amyloid Polyneuropathy and XXX cases of Familial Amyloid Cardiomyopathy in the 7MM
Transthyretin Amyloidosis (ATTR) Drug Chapters
This segment of the Transthyretin Amyloidosis (ATTR) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Current treatment options for patients with TTR amyloidosis are limited, with only symptomatic treatment and transplantation. For patients diagnosed with TTR-FAP who have a mild or moderate disease and confirmed by genetic testing and biopsy, a liver transplant is the current standard of care. However, symptomatic treatment is used to provide immediate relief.
Various mechanisms leading to TTR misfolding and fibril formation identified TTR tetramer stabilization as a rate-limiting event, leading to the development of several new pharmacologic therapies for patients with TTR-FAP. These stabilizing agents can be prescribed at an early stage in anticipation of liver transplantation, or, potentially, delaying the need for liver transplant. Drugs use in the treatment of ATTR include-Tafamidis (disease-modifying agent that kinetically stabilizes) and Diflunisal (This drug is an NSAID that stabilizes TTR tetramers in vitro, preventing disaggregation, monomer release and amyloid fibril formation by misfolded TTR monomers).
Transthyretin Amyloidosis (ATTR) Market Outlook
The Transthyretin Amyloidosis (ATTR) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
FDA has approved few drugs such as Vyndaqel (Pfizer Inc), Onpattro (Alnylam Pharmaceuticals), Tegsedi (Ionis Pharmaceuticals /Akcea Therapeutics) which are used for the treatment of Transthyretin Amyloidosis (ATTR).
Key players such as Corino Therapeutics are involved in developing therapies for Transthyretin Amyloidosis (ATTR). Expected launch of emerging therapies such as CRX-1008: Corino Therapeutics therapies will significantly impact the Transthyretin Amyloidosis (ATTR) market during the study period (2016-2027).
Transthyretin Amyloidosis (ATTR) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Transthyretin Amyloidosis (ATTR) Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
- 10 Years Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Sub-type Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Transthyretin Amyloidosis (ATTR) market
- Organize sales and marketing efforts by identifying the best opportunities for Transthyretin Amyloidosis (ATTR) market
- To understand the future market competition in the Transthyretin Amyloidosis (ATTR) market.
1. KEY INSIGHTS
2. TRANSTHYRETIN AMYLOIDOSIS (ATTR): OVERVIEW AT A GLANCE
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis (ATTR): in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis (ATTR): in 2027
3. TRANSTHYRETIN-RELATED AMYLOIDOSIS: DISEASE BACKGROUND AND OVERVIEW
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis
3.4. Causes and Clinical Manifestations
3.5. Symptoms
3.6. Pathogenesis
3.7. Diagnosis
3.7.1. Tools for evaluating TTR-FAP progression
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of ATTR
4.4. Type-specific Diagnosed Prevalent Population of hATTR in 7MM
5. EPIDEMIOLOGY BY COUNTRY
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Cases of hATTR in the United States
5.1.3. Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in the United States
5.2. European Union Five
5.3. United Kingdom
5.3.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.3.2. Type-specific Diagnosed Prevalent Cases of hATTR cases in the United Kingdom
5.3.3. Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in the United Kingdom
5.4. Germany
5.4.1. Diagnosed Prevalent Population of ATTR in Germany
5.4.2. Type-specific Diagnosed Prevalent Cases of hATTR cases in Germany
5.4.3. Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in Germany
5.5. Italy
5.5.1. Diagnosed Prevalent Population of ATTR in Italy
5.5.2. Type-specific Diagnosed Prevalent Cases of hATTR cases in Italy
5.5.3. Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in Italy
5.6. Spain
5.6.1. Diagnosed Prevalent Population of ATTR in Spain
5.6.2. Type-specific Diagnosed Prevalent Cases of hATTR cases in Spain
5.6.3. Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in Spain
5.7. France
5.7.1. Diagnosed Prevalent Population of ATTR in France
5.7.2. Type-specific Diagnosed Prevalent Cases of hATTR in France
5.7.3. Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in France
5.8. Japan
5.8.1. Diagnosed Prevalent Population of ATTR in Japan
5.8.2. Type-specific Diagnosed Prevalent Cases of hATTR in Japan
5.8.3. Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in Japan
6. 7MM DIAGNOSED PREVALENT AND SURGERY CASES OF ATTR RELATED CARPAL TUNNEL SYNDROME
6.1. Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in the United States
6.2. Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in the United Kingdom
6.3. Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Germany
6.4. Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Italy
6.5. Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Spain
6.6. Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in France
6.7. Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Japan
7. CURRENT TREATMENT AND MEDICAL PRACTICES
7.1. Treatment Guidelines
7.1.1. First European Consensus for the diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
8. UNMET NEEDS
9. MARKETED DRUGS
9.1. Key Cross Competition
9.2. Vyndaqel: Pfizer Inc.
9.2.1. Drug Description
9.2.2. Mechanism of Action
9.2.3. Regulatory Milestones
9.2.4. Advantages & Disadvantages
9.2.5. Safety and Efficacy
9.2.5.1. Ongoing trial description, 2017
9.2.5.2. Product Profile
9.3. Onpattro: Alnylam Pharmaceuticals
9.3.1. Regulatory Milestones
9.3.2. Other development activities
9.3.3. Clinical Development
9.3.4. Clinical Trials Information
9.3.4.1. Safety and Efficacy
9.3.4.2. Product Profile
9.4. Tegsedi: Ionis Pharmaceuticals /Akcea Therapeutics
9.4.1.Regulatory Milestones
9.4.1. Other development activities
9.4.2. Clinical Development
9.4.3. Clinical Trials Information
9.4.3.1. Safety and Efficacy
9.4.3.2. Product Profile
10. EMERGING THERAPIES
10.1. Key Cross Competition
10.2. CRX-1008: Corino Therapeutics
10.2.1. Regulatory Milestones
10.2.2. Other development activities
10.2.3. Clinical Development
10.2.4. Clinical Trials Information
10.2.4.1. Safety and Efficacy
10.2.4.2. Product Profile
11. TRANSTHYRETIN AMYLOIDOSIS: MARKET ANALYSIS
11.1. Key Findings
12. TRANSTHYRETIN AMYLOIDOSIS: 7 MAJOR MARKET OUTLOOK
12.1. Market size of Transthyretin Amyloidosis in 7MM
13. MARKET OUTLOOK BY COUNTRY
13.1. Transthyretin Amyloidosis: United States Market
13.1.1. The United States Market Size
13.1.2. Type-Specific Market Size of ATTR
13.1.3. Market Size by Therapies
13.2. Transthyretin Amyloidosis: EU5 Market Outlook
13.3. Germany Market Size
13.3.1. Total Market size of ATTR
13.3.2. Type-Specific Market Size of ATTR
13.3.3. Market Size by Therapies
13.4. France Market Size
13.4.1. Total Market size of ATTR
13.4.2. Type-Specific Market Size of ATTR
13.4.3. Market Size by Therapies
13.5. The United Kingdom Market Size
13.5.1. Total Market size of ATTR
13.5.2. Type-Specific Market Size of ATTR
13.5.3. Market Size by Therapies
13.6. Italy Market Size
13.6.1. Total Market size of ATTR
13.6.2. Type-Specific Market Size of ATTR
13.6.3. Market Size by Therapies
13.7. Spain Market Size
13.7.1. Total Market size of ATTR
13.7.2. Type-Specific Market Size of ATTR
13.7.3. Market Size by Therapies
13.8. Transthyretin Amyloidosis: Japan Market Analysis
13.8.1. Japan Market Size
13.8.1.1. Total Market size of ATTR
13.8.1.2. Type-Specific Market Size of ATTR
13.8.1.3. Market Size by Therapies
14. MARKET DRIVERS
15. MARKET BARRIERS
16. APPENDIX
17. REPORT METHODOLOGY
17.1. Sources Used
18. DELVEINSIGHT CAPABILITIES
19. DISCLAIMER
20. ABOUT DELVEINSIGHT
2. TRANSTHYRETIN AMYLOIDOSIS (ATTR): OVERVIEW AT A GLANCE
2.1. Market Share (%) Distribution of Transthyretin Amyloidosis (ATTR): in 2016
2.2. Market Share (%) Distribution of Transthyretin Amyloidosis (ATTR): in 2027
3. TRANSTHYRETIN-RELATED AMYLOIDOSIS: DISEASE BACKGROUND AND OVERVIEW
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis
3.4. Causes and Clinical Manifestations
3.5. Symptoms
3.6. Pathogenesis
3.7. Diagnosis
3.7.1. Tools for evaluating TTR-FAP progression
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of ATTR
4.4. Type-specific Diagnosed Prevalent Population of hATTR in 7MM
5. EPIDEMIOLOGY BY COUNTRY
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Cases of hATTR in the United States
5.1.3. Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in the United States
5.2. European Union Five
5.3. United Kingdom
5.3.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.3.2. Type-specific Diagnosed Prevalent Cases of hATTR cases in the United Kingdom
5.3.3. Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in the United Kingdom
5.4. Germany
5.4.1. Diagnosed Prevalent Population of ATTR in Germany
5.4.2. Type-specific Diagnosed Prevalent Cases of hATTR cases in Germany
5.4.3. Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in Germany
5.5. Italy
5.5.1. Diagnosed Prevalent Population of ATTR in Italy
5.5.2. Type-specific Diagnosed Prevalent Cases of hATTR cases in Italy
5.5.3. Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in Italy
5.6. Spain
5.6.1. Diagnosed Prevalent Population of ATTR in Spain
5.6.2. Type-specific Diagnosed Prevalent Cases of hATTR cases in Spain
5.6.3. Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in Spain
5.7. France
5.7.1. Diagnosed Prevalent Population of ATTR in France
5.7.2. Type-specific Diagnosed Prevalent Cases of hATTR in France
5.7.3. Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in France
5.8. Japan
5.8.1. Diagnosed Prevalent Population of ATTR in Japan
5.8.2. Type-specific Diagnosed Prevalent Cases of hATTR in Japan
5.8.3. Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in Japan
6. 7MM DIAGNOSED PREVALENT AND SURGERY CASES OF ATTR RELATED CARPAL TUNNEL SYNDROME
6.1. Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in the United States
6.2. Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in the United Kingdom
6.3. Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Germany
6.4. Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Italy
6.5. Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Spain
6.6. Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in France
6.7. Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Japan
7. CURRENT TREATMENT AND MEDICAL PRACTICES
7.1. Treatment Guidelines
7.1.1. First European Consensus for the diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
8. UNMET NEEDS
9. MARKETED DRUGS
9.1. Key Cross Competition
9.2. Vyndaqel: Pfizer Inc.
9.2.1. Drug Description
9.2.2. Mechanism of Action
9.2.3. Regulatory Milestones
9.2.4. Advantages & Disadvantages
9.2.5. Safety and Efficacy
9.2.5.1. Ongoing trial description, 2017
9.2.5.2. Product Profile
9.3. Onpattro: Alnylam Pharmaceuticals
9.3.1. Regulatory Milestones
9.3.2. Other development activities
9.3.3. Clinical Development
9.3.4. Clinical Trials Information
9.3.4.1. Safety and Efficacy
9.3.4.2. Product Profile
9.4. Tegsedi: Ionis Pharmaceuticals /Akcea Therapeutics
9.4.1.Regulatory Milestones
9.4.1. Other development activities
9.4.2. Clinical Development
9.4.3. Clinical Trials Information
9.4.3.1. Safety and Efficacy
9.4.3.2. Product Profile
10. EMERGING THERAPIES
10.1. Key Cross Competition
10.2. CRX-1008: Corino Therapeutics
10.2.1. Regulatory Milestones
10.2.2. Other development activities
10.2.3. Clinical Development
10.2.4. Clinical Trials Information
10.2.4.1. Safety and Efficacy
10.2.4.2. Product Profile
11. TRANSTHYRETIN AMYLOIDOSIS: MARKET ANALYSIS
11.1. Key Findings
12. TRANSTHYRETIN AMYLOIDOSIS: 7 MAJOR MARKET OUTLOOK
12.1. Market size of Transthyretin Amyloidosis in 7MM
13. MARKET OUTLOOK BY COUNTRY
13.1. Transthyretin Amyloidosis: United States Market
13.1.1. The United States Market Size
13.1.2. Type-Specific Market Size of ATTR
13.1.3. Market Size by Therapies
13.2. Transthyretin Amyloidosis: EU5 Market Outlook
13.3. Germany Market Size
13.3.1. Total Market size of ATTR
13.3.2. Type-Specific Market Size of ATTR
13.3.3. Market Size by Therapies
13.4. France Market Size
13.4.1. Total Market size of ATTR
13.4.2. Type-Specific Market Size of ATTR
13.4.3. Market Size by Therapies
13.5. The United Kingdom Market Size
13.5.1. Total Market size of ATTR
13.5.2. Type-Specific Market Size of ATTR
13.5.3. Market Size by Therapies
13.6. Italy Market Size
13.6.1. Total Market size of ATTR
13.6.2. Type-Specific Market Size of ATTR
13.6.3. Market Size by Therapies
13.7. Spain Market Size
13.7.1. Total Market size of ATTR
13.7.2. Type-Specific Market Size of ATTR
13.7.3. Market Size by Therapies
13.8. Transthyretin Amyloidosis: Japan Market Analysis
13.8.1. Japan Market Size
13.8.1.1. Total Market size of ATTR
13.8.1.2. Type-Specific Market Size of ATTR
13.8.1.3. Market Size by Therapies
14. MARKET DRIVERS
15. MARKET BARRIERS
16. APPENDIX
17. REPORT METHODOLOGY
17.1. Sources Used
18. DELVEINSIGHT CAPABILITIES
19. DISCLAIMER
20. ABOUT DELVEINSIGHT
LIST OF TABLES
Table 1: Diseases with symptoms that overlap with that of hATTP Amyloidosis
Table 2: Diagnostic tools for patients presenting with cardiomyopathy
Table 3: Clinical staging of TTR-FAP (based on Coutinho et al. )
Table 4: Disease staging based on PND score
Table 5: Portuguese classification system to evaluate the severity of TTR-FAP
Table 6: Diagnosed Prevalent Population of ATTR in 7MM (2016-2027)
Table 7: Type-Specific Diagnosed Prevalent Population of ATTR in 7MM (2016-2027)
Table 8: Diagnosed Prevalent Population of ATTR in the US (2016-2027)
Table 9: Type of Hereditary transthyretin amyloidosis (hATTR) cases in the US (2016-2027)
Table 10: Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in the US (2016-2027)
Table 11: Diagnosed Prevalent Population of ATTR in the United Kingdom (2016-2027)
Table 12: Type of Hereditary transthyretin amyloidosis (hATTR) cases in the United Kingdom (2016-2027)
Table 13: Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in the UK (2016-2027)
Table 14: Diagnosed Prevalent Population of ATTR in Germany (2016-2027)
Table 15: Type of Hereditary transthyretin amyloidosis (hATTR) cases in Germany (2016-2027)
Table 16: Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in Germany (2016-2027)
Table 17: Diagnosed Prevalent Population of ATTR in Italy (2016-2027)
Table 18: Type of Hereditary transthyretin amyloidosis (hATTR) cases in Italy (2016-2027)
Table 19: Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in Italy (2016-2027)
Table 20: Diagnosed Prevalent Population of ATTR in Spain (2016-2027)
Table 21: Type of Hereditary transthyretin amyloidosis (hATTR) cases in Spain (2016-2027)
Table 22: Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in Spain (2016-2027)
Table 23: Diagnosed Prevalent Population of ATTR in France (2016-2027)
Table 24: Type of Hereditary transthyretin amyloidosis (hATTR) cases in France (2016-2027)
Table 25: Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in France (2016-2027)
Table 26: Diagnosed Prevalent Population of ATTR in Japan (2016-2027)
Table 27: Type of Hereditary transthyretin amyloidosis (hATTR) cases in Japan (2016-2027)
Table 28: Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in Japan (2016-2027)
Table 29: 7MM Diagnosed Prevalent Cases of ATTR related Carpal Tunnel Syndrome (2016-2027)
Table 30: Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in the US (2016-2027)
Table 31: Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in the UK (2016-2027)
Table 32: Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Germany (2016-2027)
Table 33: Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Italy (2016-2027)
Table 34: Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Spain (2016-2027)
Table 35: Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in France (2016-2027)
Table 36: Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Japan (2016-2027)
Table 37: Treatment of clinical symptoms of transthyretin familial polyneuropathy
Table 38: Symptom management of TTR-FAP (Based on the Coutinho staging)
Table 39: Supportive non-disease modifying therapies for ATTR Cardiac amyloidosis
Table 40: Typical clinical features of the later disease (average 4 years post onset; the usual delay in diagnosis)
Table 41: TTP stages according to symptom severity
Table 42: Algorithm for the treatment of FAP
Table 43: Tafamidis, Clinical Trial Description, 2017
Table 44: Patisiran, Clinical Trial Description, 2017
Table 45: Inotersen, Clinical Trial Description, 2017
Table 46: CRX-1008, Clinical Trial Description, 2017
Table 47: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2016-2027)
Table 48: Market Size of ATTR in the US, USD Millions (2016-2027)
Table 49: Type-Specific Market Size of ATTR in the US, USD Million (2016-2027)
Table 50: Therapy Based Market Size of ATTR in the US, USD Million (2016-2027)
Table 51: Market Size of ATTR in Germany, USD Millions (2016-2027)
Table 52: Type-Specific Market Size of ATTR in Germany, USD Million (2016-2027)
Table 53: Therapy Based Market Size of ATTR in Germany, USD Million (2016-2027)
Table 54: Market Size of ATTR in France, USD Millions (2016-2027)
Table 55: Type-Specific Market Size of ATTR in France, USD Million (2016-2027)
Table 56: Therapy Based Market Size of ATTR in France, USD Million (2016-2027)
Table 57: Market Size of ATTR in the UK, USD Millions (2016-2027)
Table 58: Type-Specific Market Size of ATTR in the UK, USD Million (2016-2027)
Table 59: Therapy Based Market Size of ATTR in the UK, USD Million (2016-2027)
Table 60: Market Size of ATTR in Italy, USD Millions (2016-2027)
Table 61: Type-Specific Market Size of ATTR in Italy, USD Million (2016-2027)
Table 62: Therapy Based Market Size of ATTR in Italy, USD Million (2016-2027)
Table 63: Market Size of ATTR in Spain, USD Millions (2016-2027)
Table 64: Type-Specific Market Size of ATTR in Spain, USD Million (2016-2027)
Table 65: Therapy Based Market Size of ATTR in Spain, USD Million (2016-2027)
Table 66: Market Size of ATTR in Japan, USD Millions (2016-2027)
Table 67: Type-Specific Market Size of ATTR in Japan, USD Million (2016-2027)
Table 68: Therapy Based Market Size of ATTR in Japan, USD Million (2016-2027)
Table 1: Diseases with symptoms that overlap with that of hATTP Amyloidosis
Table 2: Diagnostic tools for patients presenting with cardiomyopathy
Table 3: Clinical staging of TTR-FAP (based on Coutinho et al. )
Table 4: Disease staging based on PND score
Table 5: Portuguese classification system to evaluate the severity of TTR-FAP
Table 6: Diagnosed Prevalent Population of ATTR in 7MM (2016-2027)
Table 7: Type-Specific Diagnosed Prevalent Population of ATTR in 7MM (2016-2027)
Table 8: Diagnosed Prevalent Population of ATTR in the US (2016-2027)
Table 9: Type of Hereditary transthyretin amyloidosis (hATTR) cases in the US (2016-2027)
Table 10: Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in the US (2016-2027)
Table 11: Diagnosed Prevalent Population of ATTR in the United Kingdom (2016-2027)
Table 12: Type of Hereditary transthyretin amyloidosis (hATTR) cases in the United Kingdom (2016-2027)
Table 13: Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in the UK (2016-2027)
Table 14: Diagnosed Prevalent Population of ATTR in Germany (2016-2027)
Table 15: Type of Hereditary transthyretin amyloidosis (hATTR) cases in Germany (2016-2027)
Table 16: Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in Germany (2016-2027)
Table 17: Diagnosed Prevalent Population of ATTR in Italy (2016-2027)
Table 18: Type of Hereditary transthyretin amyloidosis (hATTR) cases in Italy (2016-2027)
Table 19: Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in Italy (2016-2027)
Table 20: Diagnosed Prevalent Population of ATTR in Spain (2016-2027)
Table 21: Type of Hereditary transthyretin amyloidosis (hATTR) cases in Spain (2016-2027)
Table 22: Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in Spain (2016-2027)
Table 23: Diagnosed Prevalent Population of ATTR in France (2016-2027)
Table 24: Type of Hereditary transthyretin amyloidosis (hATTR) cases in France (2016-2027)
Table 25: Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in France (2016-2027)
Table 26: Diagnosed Prevalent Population of ATTR in Japan (2016-2027)
Table 27: Type of Hereditary transthyretin amyloidosis (hATTR) cases in Japan (2016-2027)
Table 28: Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in Japan (2016-2027)
Table 29: 7MM Diagnosed Prevalent Cases of ATTR related Carpal Tunnel Syndrome (2016-2027)
Table 30: Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in the US (2016-2027)
Table 31: Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in the UK (2016-2027)
Table 32: Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Germany (2016-2027)
Table 33: Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Italy (2016-2027)
Table 34: Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Spain (2016-2027)
Table 35: Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in France (2016-2027)
Table 36: Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Japan (2016-2027)
Table 37: Treatment of clinical symptoms of transthyretin familial polyneuropathy
Table 38: Symptom management of TTR-FAP (Based on the Coutinho staging)
Table 39: Supportive non-disease modifying therapies for ATTR Cardiac amyloidosis
Table 40: Typical clinical features of the later disease (average 4 years post onset; the usual delay in diagnosis)
Table 41: TTP stages according to symptom severity
Table 42: Algorithm for the treatment of FAP
Table 43: Tafamidis, Clinical Trial Description, 2017
Table 44: Patisiran, Clinical Trial Description, 2017
Table 45: Inotersen, Clinical Trial Description, 2017
Table 46: CRX-1008, Clinical Trial Description, 2017
Table 47: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2016-2027)
Table 48: Market Size of ATTR in the US, USD Millions (2016-2027)
Table 49: Type-Specific Market Size of ATTR in the US, USD Million (2016-2027)
Table 50: Therapy Based Market Size of ATTR in the US, USD Million (2016-2027)
Table 51: Market Size of ATTR in Germany, USD Millions (2016-2027)
Table 52: Type-Specific Market Size of ATTR in Germany, USD Million (2016-2027)
Table 53: Therapy Based Market Size of ATTR in Germany, USD Million (2016-2027)
Table 54: Market Size of ATTR in France, USD Millions (2016-2027)
Table 55: Type-Specific Market Size of ATTR in France, USD Million (2016-2027)
Table 56: Therapy Based Market Size of ATTR in France, USD Million (2016-2027)
Table 57: Market Size of ATTR in the UK, USD Millions (2016-2027)
Table 58: Type-Specific Market Size of ATTR in the UK, USD Million (2016-2027)
Table 59: Therapy Based Market Size of ATTR in the UK, USD Million (2016-2027)
Table 60: Market Size of ATTR in Italy, USD Millions (2016-2027)
Table 61: Type-Specific Market Size of ATTR in Italy, USD Million (2016-2027)
Table 62: Therapy Based Market Size of ATTR in Italy, USD Million (2016-2027)
Table 63: Market Size of ATTR in Spain, USD Millions (2016-2027)
Table 64: Type-Specific Market Size of ATTR in Spain, USD Million (2016-2027)
Table 65: Therapy Based Market Size of ATTR in Spain, USD Million (2016-2027)
Table 66: Market Size of ATTR in Japan, USD Millions (2016-2027)
Table 67: Type-Specific Market Size of ATTR in Japan, USD Million (2016-2027)
Table 68: Therapy Based Market Size of ATTR in Japan, USD Million (2016-2027)
LIST OF FIGURES
Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Therapeutic Targets in TTR Amyloidosis Pathogenesis
Figure 6: Red flag symptoms of hATTR Amyloidosis
Figure 7: Clinical findings indicative of hATTR
Figure 8: Diagnosed Prevalent Population of ATTR in 7MM (2016-2027)
Figure 9: Type-specific Diagnosed Prevalent Population of ATTR in 7MM (2016-2027)
Figure 10: Diagnosed Prevalent Population of ATTR in the US (2016-2027)
Figure 11: Type of Hereditary Transthyretin Amyloidosis (hATTR) cases in the US (2016-2027)
Figure 12: Stage-specific Diagnosed Prevalent Population of hATTR in the US (2016-2027)
Figure 13: Diagnosed Prevalent Population of ATTR in the UK (2016-2027)
Figure 14: Type of Hereditary transthyretin amyloidosis (hATTR) cases in the UK (2016-2027)
Figure 15: Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in the UK (2016-2027)
Figure 16: Diagnosed Prevalent Population of ATTR in Germany (2016-2027)
Figure 17: Type of Hereditary transthyretin amyloidosis (hATTR) cases in Germany (2016-2027)
Figure 18: Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in Germany (2016-2027)
Figure 19: Diagnosed Prevalent Population of ATTR in Italy (2016-2027)
Figure 20: Type of Hereditary transthyretin amyloidosis (hATTR) cases in Italy (2016-2027)
Figure 21: Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in Italy (2016-2027)
Figure 22: Diagnosed Prevalent Population of ATTR in Spain (2016-2027)
Figure 23: Type of Hereditary transthyretin amyloidosis (hATTR) cases in Spain (2016-2027)
Figure 24: Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in Spain (2016-2027)
Figure 25: Diagnosed Prevalent Population of ATTR in France (2016-2027)
Figure 26: Type of Hereditary transthyretin amyloidosis (hATTR) cases in France (2016-2027)
Figure 27: Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in France (2016-2027)
Figure 28: Diagnosed Prevalent Population of ATTR in Japan (2016-2027)
Figure 29: Type of Hereditary transthyretin amyloidosis (hATTR) cases in Japan (2016-2027)
Figure 30: Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in Japan (2016-2027)
Figure 31: 7MM Diagnosed Prevalent Cases of ATTR related Carpal Tunnel Syndrome (2016-2027)
Figure 32: Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in the US (2016-2027)
Figure 33: Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in the UK (2016-2027)
Figure 34: Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Germany (2016-2027)
Figure 35: Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Italy (2016-2027)
Figure 36: Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Spain (2016-2027)
Figure 37: Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in France (2016-2027)
Figure 38: Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Japan (2016-2027)
Figure 39: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2016-2027)
Figure 42: Market Size of ATTR in the US, USD Millions (2016-2027)
Figure 43: Type-Specific market of ATTR in the US, USD Million (2016-2027)
Figure 44: Therapies Based market of ATTR in the US, USD Million (2016-2027)
Figure 45: Market Size of ATTR in Germany, USD Millions (2016-2027)
Figure 46: Type-Specific market of ATTR in Germany, USD Million (2016-2027)
Figure 47: Therapies Based market of ATTR in Germany, USD Million (2016-2027)
Figure 48: Market Size of ATTR in France, USD Millions (2016-2027)
Figure 49: Type-Specific market of ATTR in France, USD Million (2016-2027)
Figure 50: Therapies Based market of ATTR in France, USD Million (2016-2027)
Figure 51: Market Size of ATTR in the UK, USD Millions (2016-2027)
Figure 52: Type-Specific market of ATTR in the UK, USD Million (2016-2027)
Figure 53: Therapies Based market of ATTR in the UK, USD Million (2016-2027)
Figure 54: Market Size of ATTR in Italy, USD Millions (2016-2027)
Figure 55: Type-Specific market of ATTR in Italy, USD Million (2016-2027)
Figure 56: Therapies Based market of ATTR in Italy, USD Million (2016-2027)
Figure 57: Market Size of ATTR in Spain, USD Millions (2016-2027)
Figure 58: Type-Specific market of ATTR in Spain, USD Million (2016-2027)
Figure 59: Therapies Based market of ATTR in Spain, USD Million (2016-2027)
Figure 60: Market Size of ATTR in Japan, USD Millions (2016-2027)
Figure 61: Type-Specific market of ATTR in Japan, USD Million (2016-2027)
Figure 62: Therapies Based market of ATTR in Japan, USD Million (2016-2027)
Figure 63: Market Drivers
Figure 64: Market Barriers
Figure 1: Types of Transthyretin Amyloidosis
Figure 2: Causes of Transthyretin Amyloidosis
Figure 3: Symptoms of Transthyretin Amyloidosis
Figure 4: Pathogenesis of Transthyretin Amyloidosis
Figure 5: Therapeutic Targets in TTR Amyloidosis Pathogenesis
Figure 6: Red flag symptoms of hATTR Amyloidosis
Figure 7: Clinical findings indicative of hATTR
Figure 8: Diagnosed Prevalent Population of ATTR in 7MM (2016-2027)
Figure 9: Type-specific Diagnosed Prevalent Population of ATTR in 7MM (2016-2027)
Figure 10: Diagnosed Prevalent Population of ATTR in the US (2016-2027)
Figure 11: Type of Hereditary Transthyretin Amyloidosis (hATTR) cases in the US (2016-2027)
Figure 12: Stage-specific Diagnosed Prevalent Population of hATTR in the US (2016-2027)
Figure 13: Diagnosed Prevalent Population of ATTR in the UK (2016-2027)
Figure 14: Type of Hereditary transthyretin amyloidosis (hATTR) cases in the UK (2016-2027)
Figure 15: Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in the UK (2016-2027)
Figure 16: Diagnosed Prevalent Population of ATTR in Germany (2016-2027)
Figure 17: Type of Hereditary transthyretin amyloidosis (hATTR) cases in Germany (2016-2027)
Figure 18: Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in Germany (2016-2027)
Figure 19: Diagnosed Prevalent Population of ATTR in Italy (2016-2027)
Figure 20: Type of Hereditary transthyretin amyloidosis (hATTR) cases in Italy (2016-2027)
Figure 21: Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in Italy (2016-2027)
Figure 22: Diagnosed Prevalent Population of ATTR in Spain (2016-2027)
Figure 23: Type of Hereditary transthyretin amyloidosis (hATTR) cases in Spain (2016-2027)
Figure 24: Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in Spain (2016-2027)
Figure 25: Diagnosed Prevalent Population of ATTR in France (2016-2027)
Figure 26: Type of Hereditary transthyretin amyloidosis (hATTR) cases in France (2016-2027)
Figure 27: Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in France (2016-2027)
Figure 28: Diagnosed Prevalent Population of ATTR in Japan (2016-2027)
Figure 29: Type of Hereditary transthyretin amyloidosis (hATTR) cases in Japan (2016-2027)
Figure 30: Stage-Specific Diagnosed Prevalent Population of Familial Amyloid Polyneuropathy in Japan (2016-2027)
Figure 31: 7MM Diagnosed Prevalent Cases of ATTR related Carpal Tunnel Syndrome (2016-2027)
Figure 32: Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in the US (2016-2027)
Figure 33: Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in the UK (2016-2027)
Figure 34: Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Germany (2016-2027)
Figure 35: Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Italy (2016-2027)
Figure 36: Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Spain (2016-2027)
Figure 37: Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in France (2016-2027)
Figure 38: Diagnosed Prevalent and Surgery Cases of ATTR related Carpal Tunnel Syndrome in Japan (2016-2027)
Figure 39: Current treatment pathway for patients with Transthyretin Amyloidosis with polyneuropathy
Figure 40: Unmet Needs of Transthyretin Amyloidosis
Figure 41: 7 Major Market Size of Transthyretin Amyloidosis in USD Million (2016-2027)
Figure 42: Market Size of ATTR in the US, USD Millions (2016-2027)
Figure 43: Type-Specific market of ATTR in the US, USD Million (2016-2027)
Figure 44: Therapies Based market of ATTR in the US, USD Million (2016-2027)
Figure 45: Market Size of ATTR in Germany, USD Millions (2016-2027)
Figure 46: Type-Specific market of ATTR in Germany, USD Million (2016-2027)
Figure 47: Therapies Based market of ATTR in Germany, USD Million (2016-2027)
Figure 48: Market Size of ATTR in France, USD Millions (2016-2027)
Figure 49: Type-Specific market of ATTR in France, USD Million (2016-2027)
Figure 50: Therapies Based market of ATTR in France, USD Million (2016-2027)
Figure 51: Market Size of ATTR in the UK, USD Millions (2016-2027)
Figure 52: Type-Specific market of ATTR in the UK, USD Million (2016-2027)
Figure 53: Therapies Based market of ATTR in the UK, USD Million (2016-2027)
Figure 54: Market Size of ATTR in Italy, USD Millions (2016-2027)
Figure 55: Type-Specific market of ATTR in Italy, USD Million (2016-2027)
Figure 56: Therapies Based market of ATTR in Italy, USD Million (2016-2027)
Figure 57: Market Size of ATTR in Spain, USD Millions (2016-2027)
Figure 58: Type-Specific market of ATTR in Spain, USD Million (2016-2027)
Figure 59: Therapies Based market of ATTR in Spain, USD Million (2016-2027)
Figure 60: Market Size of ATTR in Japan, USD Millions (2016-2027)
Figure 61: Type-Specific market of ATTR in Japan, USD Million (2016-2027)
Figure 62: Therapies Based market of ATTR in Japan, USD Million (2016-2027)
Figure 63: Market Drivers
Figure 64: Market Barriers
